.jpg)
Amgen reports more Phase 3 Uplizna data in myasthenia gravis ahead of FDA filing
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s case for label expansion before a planned FDA filing this quarter. The drugmaker reported 52-week results ...
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s case for label expansion before a planned FDA filing this quarter.
The drugmaker reported 52-week results ...
